Metraipolis › archive › dc_93bfb1500f24

Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study — Europe PMC PMID:41196386

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41196386
DOI
10.1007/s00415-[numero omesso]-w
License (as archived)
solo-consultazione
Archived
2026-11-09T02:18:08.526Z
SHA-256 of the archived text
393ef35d81f6d6e6a96d9eb032823a17ad5b130b463c727ce583ba0a862fb9d9
Stable URL of this page
https://metraipolis.com/documento/dc_93bfb1500f24

How to cite

Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study — Europe PMC PMID:41196386 — Europe PMC (en), https://europepmc.org/article/MED/41196386 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_93bfb1500f24 (Metraipolis archive dc_93bfb1500f24, sha256 393ef35d81f6d6e6a96d9eb032823a17ad5b130b463c727ce583ba0a862fb9d9)
BibTeX
@misc{dc93bfb1500f24,
  title = {Switch from intravenous anti-CD20 therapy to subcutaneous ofatumumab in patients with relapsing MS: results from the OLIKOS study — Europe PMC PMID:41196386},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41196386},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_93bfb1500f24; sha256 393ef35d81f6d6e6a96d9eb032823a17ad5b130b463c727ce583ba0a862fb9d9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41196386. Agents can read the archived copy with the MCP tool read_document.